Two Indian Nationals Indicted in Counterfeit Ozempic Smuggling Scheme, DOJ Says

A federal grand jury has indicted two Indian nationals on charges of smuggling and selling counterfeit versions of the popular weight-loss drug Ozempic, the U.S. Department of Justice announced on Tuesday. The defendants allegedly sourced the fake medication from China and distributed it within the United States.

Details of the Indictment

The indictment charges Swapnadip Roy and Vicky Ramancha with multiple federal crimes, including smuggling and selling counterfeit drugs, conspiracy to commit smuggling, and conspiracy to defraud the United States. According to the Justice Department, Roy was extradited from Italy and pleaded not guilty to the charges on Tuesday. If convicted, the defendants face a maximum sentence of up to 71 years in prison.

The Alleged Smuggling Operation

Prosecutors allege the scheme operated between July 2023 and April 2024. During this period, Roy and Ramancha are accused of obtaining counterfeit Ozempic from sources in China and selling it to distributors in the U.S. at discounted prices.

Ad

The counterfeit products were designed to deceive buyers, featuring packaging, inserts, and labels that mimicked authentic Ozempic. The Justice Department noted that the operation allegedly continued even after the U.S. Food and Drug Administration (FDA) seized a shipment of the counterfeit drugs and issued a public warning about them in December 2023.

Market Context and Implications

The high demand and cost of authentic Ozempic, which can run hundreds of dollars per month for patients, has created a lucrative black market for counterfeit versions. This case highlights the significant public health risks associated with unregulated pharmaceuticals and the focus of U.S. law enforcement on protecting the integrity of the nation's drug supply chain. Such schemes not only endanger consumers but also pose a reputational risk to legitimate pharmaceutical manufacturers.